NCT04198350 (EYELETS) is a NA clinical trial of Islet implantation in Type 1 Diabetes, sponsored by Imperial College London.

Who is sponsoring NCT04198350?

NCT04198350 is sponsored by Imperial College London.

What drugs are being tested in NCT04198350?

Interventions in NCT04198350: Islet implantation.

What condition does NCT04198350 study?

NCT04198350 studies Type 1 Diabetes, Visual Impairment.

Is NCT04198350 still recruiting?

NCT04198350 is currently withdrawn. Last updated 3 September 2025.

Last reviewed 2025-09-03 · How we verify

NCT04198350: EYELETS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pancreatic Islet Transplantation to the Anterior Chamber of the Eye

Withdrawn NA Last updated 3 September 2025

What this trial tests

NA trial testing Islet implantation in Type 1 Diabetes. Withdrawn.

Timeline

1 September 2022

Primary endpoint
31 August 2025

31 August 2025

Quick facts

Lead sponsor	Imperial College London
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	1 September 2022
Primary completion	31 August 2025
Estimated completion	31 August 2025
Sites	1 location across United Kingdom

Drugs / interventions tested

Islet implantation

Conditions studied

Type 1 Diabetes — all drugs for Type 1 Diabetes →
Visual Impairment — all drugs for Visual Impairment →

Sponsor

Imperial College London

Who can join

18 and older, any sex, with Type 1 Diabetes or Visual Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase II prospective, interventional, open-labeled, proof-of-concept study. 2 years per participant, 2 years 6 months in total Total n=6 The primary objective is to assess the safety of human pancreatic islet transplantation into the ACE of participants with T1D. Safety analyses will involve examination of the incidence, severity, and type of treatment emergent AEs reported, and changes in vital signs, ophthalmic status and laboratory test results from baseline (Day 0 pre-transplantation) to specified time points throughout the study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Type 1 Diabetes

Currently open trials in the same condition.

NCT07061574 — A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New On · Phase 1, PHASE2 · recruiting
NCT07360080 — Long-Term Outcomes of Teplizumab in Routine Clinical Care · recruiting
NCT07457580 — Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) · recruiting
NCT07212179 — Safety and Feasibility of a Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With Type 1 · NA · recruiting
NCT07287943 — To Study the Efficacy and Safety of Medtronic 780G Insulin Pump in People With Gastroparesis and Type 1 Diabetes. · NA · recruiting

Other Imperial College London trials

Trials by the same sponsor.

NCT06035861 — Endothelial Cell Activation and Total Pulmonary Resistance in PAH · NA · not yet recruiting
NCT07397455 — Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants · Phase 1 · not yet recruiting
NCT07422532 — A Multi-centre Trial to Assess the Efficacy and Safety of the Omnipod 5 System in People With Type 2 Diabetes Undergoing · NA · not yet recruiting
NCT07389031 — Maralixibat for Intrahepatic Cholestasis of Pregnancy · Phase 2 · not yet recruiting
NCT07358897 — Gender Affirming Hormone Therapy and Immune Function in Trans Individuals - The GIFT Study · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04198350 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Imperial College London
Last refreshed: 3 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04198350.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing